Stress Urinary Incontinence (Female)
Stress urinary incontinence (SUI) is the involuntary leakage of urine with physical exertion, coughing, sneezing, or any activity that raises intra-abdominal pressure. It is the most common type of urinary incontinence, affecting approximately 46% of adult women when defined as any symptoms in the previous year, with prevalence peaking at ~50% among women aged 40 and older.[2] SUI causes significant physical, emotional, and social distress and is a leading driver of gynecologic and urogynecologic referral.
ACP Guideline: The American College of Physicians recommends initiating treatment with pelvic floor muscle training (PFMT) in women with stress, urgency, or mixed urinary incontinence — the first-line approach for SUI is behavioral intervention.[1]
This page covers the clinical framework and diagnostic workup. For procedural selection and comparative treatment options, see the Female SUI treatment database.
Pathophysiology
SUI occurs when intra-abdominal pressure transiently exceeds urethral closure pressure, allowing urine to escape.[2][3] Two primary mechanisms account for most cases:
Urethral hypermobility Loss of pelvic floor muscular support or vaginal connective tissue prevents the urethra and bladder neck from assuming a stable closed position in response to pressure increases. Weakness of support structures and collagen-dependent tissue damage are central. This is the predominant mechanism in most post-partum and post-menopausal patients.
DeLancey's hammock hypothesis. The urethra rests on a supportive layer (anterior vaginal wall + endopelvic fascia) anchored laterally to the arcus tendineus and levator ani. With intact support, a cough compresses the urethra against this stable backboard and the lumen closes (continent). When the lateral (paravaginal) attachments fail, the hammock sags, the urethra becomes hypermobile, and the cough no longer compresses it — stress leakage. This is why a midurethral sling restores continence: it re-creates the suburethral backboard. (Original WARWIKI schematic)
Intrinsic sphincter deficiency (ISD) Loss of intrinsic urethral mucosal and muscular tone results in poor urethral coaptation and a reduced resting urethral closure pressure (<20–60 cmH₂O depending on criteria). ISD produces more severe leakage, often with minimal provocation, and is associated with prior urethral surgery, radiation, and neurological injury.
In practice, many patients exhibit a combination of both mechanisms.
Risk Factors
| Risk Factor | Notes |
|---|---|
| Vaginal delivery | ~2× risk vs cesarean; risk increases with parity and instrumental delivery |
| Increasing parity | Cumulative effect with each vaginal birth |
| Obesity / elevated BMI | Chronic elevated intra-abdominal pressure; weight loss reduces severity |
| Age and menopause | Estrogen deficiency reduces urethral mucosal coaptation; prevalence peaks 40–60 years |
| White race | Higher prevalence than Black or Hispanic women |
| Pelvic surgery | Hysterectomy disrupts endopelvic fascia and autonomic innervation |
| Conditions raising IAP | Chronic cough, constipation, heavy lifting, high-impact exercise |
| Smoking | Chronic cough; collagen effects |
| Connective tissue disorders | Joint hypermobility syndromes associated with PFD |
Diagnostic Evaluation
History
Key elements to assess:
- Leakage pattern: Predictable with cough, sneeze, Valsalva, exercise, position change
- Severity: Frequency (daily, weekly), volume (small drops vs soaking), pad use and type
- Degree of bother: Drives treatment urgency and goal-setting
- Coexisting symptoms: Urgency, urgency incontinence, incomplete emptying, prolapse symptoms, fecal incontinence, dyspareunia
- Obstetric/surgical history: Deliveries, episiotomies, prior anti-incontinence surgery
- Medication review: Diuretics, α-blockers, anticholinergics, caffeine, alcohol
Physical Examination
| Finding | Significance |
|---|---|
| Vulvovaginal atrophy | Common in postmenopausal women; may worsen symptoms |
| Skin maceration / excoriation | Severity of leakage; hygiene counseling |
| Pelvic organ prolapse | May mask or worsen SUI; assess all three compartments |
| Pelvic floor muscle strength | Baseline for PFMT; assess ability to contract voluntarily |
| Urethral hypermobility | Cotton swab (Q-tip) test — rotation >30° from horizontal indicates hypermobility |
| Urethral diverticulum / fistula | Rule out anatomical causes of leakage |
Urinalysis
Mandatory to exclude UTI, hematuria, glycosuria, and pyuria before attributing symptoms to SUI.[2][3]
Voiding Diary
A 1–3 day fluid intake and voiding diary identifies modifiable factors (total intake, caffeine, nocturnal patterns) and quantifies leakage frequency when history is insufficient.[3]
Cough Stress Test
Patient voids to comfortable fullness (~300 mL), then coughs or Valsalvas forcefully in standing or lithotomy position. Immediate urethral leakage synchronous with the cough confirms SUI. Positive predictive value 78–97%.[2][3]
Postvoid Residual
Performed by catheterization or bladder ultrasound. Important before surgical planning to exclude incomplete emptying.
Urodynamic Testing
Not required before surgery for uncomplicated, pure stress-predominant SUI with a positive cough stress test and PVR <150 mL.[2][6] Basic office evaluation is non-inferior to multichannel urodynamics in this group. Urodynamics are indicated for:
- Mixed incontinence with significant urgency component
- Prior anti-incontinence surgery (failed or new evaluation)
- Neurogenic lower urinary tract dysfunction
- Elevated PVR or voiding dysfunction
- Discordance between symptoms and examination findings
Treatment
Step 1 — Conservative (First-Line)
Pelvic Floor Muscle Training (PFMT)
The cornerstone of first-line management and the ACP-recommended initial treatment for all women with SUI.[1] PFMT involves repeated voluntary pelvic floor contractions taught and supervised by a trained physiotherapist or pelvic health specialist.
Key evidence:
- Cure rates, symptom improvement, satisfaction, and QoL all significantly improved vs control[4][7][9]
- ~50% of women with stress-predominant incontinence are satisfied at 1 year with supervised PFMT[6]
- More intensive programs with adherence support are more effective than unsupervised instruction[7]
- Clinically successful treatment is defined as ≥50% reduction in incontinence episode frequency[1]
Adjunctive physical therapy modalities:
| Modality | Evidence |
|---|---|
| Biofeedback | PFMT + biofeedback superior to PFMT alone |
| Vaginal cones | Weighted resistance training; modest benefit |
| Electrical stimulation | Benefits quality of life outcomes |
| Intravaginal pessaries | Incontinence ring/dish type; improves QoL; may be combined with PFMT |
Lifestyle Modifications
| Modification | Rationale |
|---|---|
| Weight loss | Even 5–10% reduction improves SUI in overweight/obese women[6][9] |
| Fluid management | Limit total intake to ≤2 L/day; avoid excessive restriction |
| Caffeine reduction | Even 1 cup/day associated with incontinence; trial of elimination warranted |
| Reduce nocturnal fluids | For nocturia-associated symptoms |
| Frequent voiding | Reduce bladder volume at times of activity |
| Constipation management | Reduces chronic Valsalva and pelvic floor strain |
Step 2 — Surgical (Second-Line)
Reserved for patients with inadequate response to conservative therapy, or may be first-line based on severity and patient preference after shared decision-making.
Midurethral Slings (Synthetic Mesh)
The most common primary surgical treatment for female SUI — well-established efficacy data:
| Metric | Midurethral Sling | PFMT (comparison) |
|---|---|---|
| Subjective cure at 1 year | 85% | 53% |
| Objective cure at 1 year | 76.5% | 58.8% |
| Cross-over from PFMT → surgery | 49% at trial completion | — |
| Cross-over from surgery → PFMT | 11% | — |
Compared to other surgical options:[6]
- Equivalent to traditional autologous fascial slings, open Burch colposuspension, and laparoscopic colposuspension in efficacy
- Fewer adverse events than suburethral fascial slings
- Less voiding dysfunction than open colposuspension
Note on mesh: FDA actions (2011, 2019) restricted transvaginal mesh for prolapse but midurethral slings for SUI retain regulatory approval given favorable risk-benefit data. Mesh-related concerns have increased patient hesitancy; informed discussion is essential.[8]
Types of midurethral slings:
| Type | Approach | Notes |
|---|---|---|
| Retropubic (TVT) | Behind pubic bone | Highest long-term data; bladder injury risk ~3–5% |
| Transobturator (TOT/TVT-O) | Lateral obturator | Lower bladder injury risk; higher groin/thigh pain rate |
| Single-incision mini-sling | Anchored midurethral | Shorter procedure; long-term data still maturing |
Autologous Fascial Sling
Pubovaginal sling using rectus fascia or fascia lata. Established robust evidence; preferred when mesh is contraindicated or patient declines synthetic materials. Higher voiding dysfunction rate than midurethral slings; durable long-term results.[8][9]
Burch Colposuspension
Open or laparoscopic retropubic colposuspension (paravaginal sutures to Cooper's ligament). Equivalent to midurethral sling in appropriately selected patients. Particularly applicable at the time of abdominal sacrocolpopexy — concurrent Burch reduces de novo post-operative SUI.[6]
Urethral Bulking Agents
Periurethral or transurethral injection of bulking material (polyacrylamide hydrogel, calcium hydroxylapatite, dextranomer/hyaluronic acid). Office-based, minimally invasive option. Lower cure rates than slings; useful in patients unfit for anesthesia, prior mesh failure, ISD-predominant disease, or as temporizing measure.[8]
Artificial Urinary Sphincter
Reserved for severe, complicated SUI — particularly ISD after prior failed surgery or radiation. High-quality data limited for this indication in women; see AUS article.[6]
Pharmacotherapy
Medical therapies for SUI are generally not recommended — current evidence-based pharmacological treatments primarily address urgency incontinence (antimuscarinics, β3-agonists), not SUI.[6]
Duloxetine (SNRI, not FDA-approved for SUI in the US) has modest evidence for symptom improvement but significant side effects limiting use; not in routine clinical practice in North America.
Emerging Therapies
Vaginal laser therapy (CO₂ fractional laser, Er:YAG laser) has been investigated for SUI. A 2025 Cochrane review (Ippolito et al.) provides updated evidence; this remains an evolving area without established guideline support.[5]
Outcomes
| Treatment | Expected Outcome |
|---|---|
| PFMT (supervised) | ~50% satisfaction at 1 year; best with early initiation and professional supervision |
| Midurethral sling | 85% subjective cure, 76.5% objective cure at 1 year |
| Burch colposuspension | Equivalent to MUS; ~80% success at 1 year |
| Autologous fascial sling | Durable; ~85% success; higher voiding dysfunction rate |
| Bulking agents | 50–60% short-term improvement; lower durability |
Clinical Approach Summary
Recommended stepwise approach for a woman presenting with SUI:
- Assess bother and QoL impact — drives urgency and goals of treatment
- Quantify leakage — frequency, volume, pad use, pad weight test if available
- Pelvic exam — prolapse assessment, muscle function, Q-tip test, cough stress test
- Urinalysis — rule out UTI
- First-line: Prescribe supervised PFMT ± lifestyle modifications (weight loss, caffeine reduction)
- Adjuncts: Incontinence pessary if patient prefers non-surgical option or awaits PFMT response
- Persistent symptoms: Refer with shared decision-making re: sling vs colposuspension vs bulking; obtain PVR ± urodynamics per complexity
Referral Indications
- Significant pelvic organ prolapse (concurrent repair consideration)
- Elevated PVR / voiding dysfunction
- Failed prior anti-incontinence surgery
- Mixed incontinence with dominant urgency component
- Consideration of surgical management
- Neurological comorbidity
See Also
- Female SUI treatment database
- Pelvic Floor Physical Therapy
- Behavioral Therapy for Urinary Incontinence
- Weight Loss for Urinary Incontinence
- Retropubic Mid-Urethral Sling
- Transobturator Mid-Urethral Sling
- Single-Incision Mini-Sling
- Autologous Fascial Pubovaginal Sling
- Burch Colposuspension
- Urethral Bulking Agents
- Artificial Urinary Sphincter
References
1. Qaseem A, Dallas P, Forciea MA, et al. Nonsurgical management of urinary incontinence in women: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161(6):429–40. PMID 25222388
2. Wu JM. Stress incontinence in women. N Engl J Med. 2021;384(25):2428–36. PMID 34133856
3. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. JAMA. 2017;318(16):1592–1604. PMID 29067433
4. Ayeleke RO, Hay-Smith EJ, Omar MI. Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women. Cochrane Database Syst Rev. 2015;(11):CD010551. PMID 26558551
5. Ippolito GM, Crescenze IM, Sitto H, et al. Vaginal lasers for treating stress urinary incontinence in women. Cochrane Database Syst Rev. 2025;7:CD013643. doi:10.1002/14651858.CD013643.pub2
6. ACOG Practice Bulletin No. 155: Urinary incontinence in women. Obstet Gynecol. 2015;126(5):e66–81. PMID 26488524
7. Todhunter-Brown A, Hazelton C, Campbell P, et al. Conservative interventions for treating urinary incontinence in women: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. 2022;9:CD012337. PMID 36047951
8. Moris L, Heesakkers J, Nitti V, et al. Prevalence, diagnosis, and management of stress urinary incontinence in women: a collaborative review. Eur Urol. 2025;87(3):292–301. PMID 39743413
9. O'Reilly N, Nelson HD, Conry JM, et al. Screening for urinary incontinence in women: a recommendation from the Women's Preventive Services Initiative. Ann Intern Med. 2018;169(5):320–28. PMID 30105373